SCHEMBL502898

SCHEMBL502898

CC(C)(C)OC(=O)N1CCC(c2ccc(NC(=O)c3ccc(Cl)cc3)cc2)C1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.59
MAPT P10636 2/20 0.59
THRB P10828 1/20 0.59
NAMPT P43490 1/20 0.55
LMNA P02545 2/20 0.54
NPC1 O15118 1/20 0.54
NFKB1 P19838 1/20 0.54
RAB9A P51151 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HRH3 Q9Y5N1 1/20 0.52
ABL1 P00519 1/20 0.51
RIN1 Q13671 1/20 0.51
NR3C1 P04150 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PTPN2 P17706 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPN6 P29350 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL502899 1.00 TP53 (0.59) TP53MAPTTHRBNAMPTLMNA
SCHEMBL14454767 0.91 NAMPT (0.59) TP53MAPTTHRBNAMPTHRH3
SCHEMBL12279642 0.88 PDE4B (0.58) TP53MAPTNAMPTLMNANPC1
SCHEMBL22988918 0.88 PDE4B (0.58) TP53MAPTNAMPTLMNANPC1
SCHEMBL503192 0.87 MAPT (0.54) TP53MAPTTHRBNAMPTLMNA
SCHEMBL503191 0.87 MAPT (0.54) TP53MAPTTHRBNAMPTLMNA
SCHEMBL21743086 0.84 NAMPT (0.56) TP53MAPTNAMPTNPC1RAB9A
SCHEMBL28362371 0.84 NAMPT (0.56) TP53MAPTNAMPTNPC1RAB9A
SCHEMBL11889629 0.84 NAMPT (0.64) TP53MAPTTHRBNAMPTNPC1
SCHEMBL1990925 0.84 NPC1 (0.55) TP53MAPTTHRBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9132136-B2 Pharmaceutical combination HOFFMANN-LA ROCHE INC. (US) 2015-09-15 US disclosed
US-20130345201-A1 PHARMACEUTICAL COMBINATION HOFFMANN-LA ROCHE INC. (US) 2013-12-26 US disclosed
EP-2600853-A1 COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2013-06-12 EP disclosed
WO-2012016879-A1 COMBINATIONS COMPRISING ATYPICAL ANTIPSYCHOTICS AND TAAR1 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-02-09 WO disclosed
US-20120028964-A1 PHARMACEUTICAL COMBINATION SEMINIS VEGETABLE SEEDS, INC. 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028964-A1 PHARMACEUTICAL COMBINATION TAAR1, TAAR5, MC2R TP53 4796/4885MAPT 703/4885THRB 155/4885
US-20130345201-A1 PHARMACEUTICAL COMBINATION TAAR1, TAAR5, MC2R TP53 4796/4885MAPT 703/4885THRB 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.